2021年山东普通研究生入学考试准考证打印时间已经发布了!了解一下

发布时间:2020-05-13


小伙伴们,近些年考研热一直居高不下,51题库考试学习网相信越来越多的同学会选择本科毕业先考一波研,但饮恨考研的人每年都不下百万,如果想考研顺利,上岸成功,除去考生自身的努力之外,考研择校尤其重要。如若选对了学校,基本上是向成功迈出了一大半,反之读研就变得遥遥无期。那么问题来了,2021年山东普通研究生入学考试准考证打印时间了解了吗?51题库考试学习网帮大家了解到2021年普通研究生入学考试准考证打印时间暂未公布,考生可以参考2020年准考证的打印时间。

根据中国研究生招生信息网公布的《2020年全国硕士研究生招生工作管理规定》的得知,2020年考研准考证打印时间已公布,具体如下:
【考研准考证打印时间】
2020年考研准考证打印时间为2019年12月14日至12月24日,考生可凭网报用户名和密码登录“研招网”自行下.载打印《准考证》。《准考证》使用A4幅面白纸打印,正、反两面在使用期间不得涂改或书写。考生凭下.载打印的《准考证》及居民身份证参加初试和复试。
请考生务必妥善保管个人网报用户名、密码及《准考证》、居民身份证等证件,避免泄露丢失造成损失。
【考研准考证打印网址】
考生在规定时间内登录“中国研究生招生信息网”(公网网址:http://yz.chsi.com.cn,教育网址:http://yz.chsi.cn),打印准考证。
查询时间
根据教育部的安排,2020年山东硕士研究生招生考试的评卷工作将于2020年春节前后完成,2020年山东考研成绩查询入口将于2020年2月15日后开通,考生可登录《山东招生考试信息港》或《中国研究生招生信息网》查询成绩,考生也可通过招生单位公布的方式查询成绩。
查询方式
山东2020年考研成绩查询入口于2020年2月15日左右开通后,考生可登录《山东招生考试信息港》或者《中国研究生招生信息网》查询成绩,也可直接点击下方链接进行成绩查询。
查询网站
注意:部分院校考研成绩查询系统开通后,希望考生提前注意,由可能查询的人太多,希望家不用着急,稍等一下。
2020年山东考研成绩查询网站1:山东教育考试院
2020年山东考研成绩查询网站2:中国研究生招生信息网
以上就是51题库考试学习网给考生们带来的普通研究生考试相关资讯,研究生考试报名人数众多,竞争比较大,51题库考试学习网衷心的祝愿各位考生都能考上理想院校!


下面小编为大家准备了 研究生入学 的相关考题,供大家学习参考。

利用百分位数的计算公式可以计算出任意分数在整个分数分布中所处的百分位置,称为该分数的()

A.百分等级
B.百分数
C.百分比
D.百分位差
答案:A
解析:
描述统计;相对量数。 这个就是百分等级的定义。

下列哪种情况下,基础代谢率明显升高?

A.肢端肥大症 B.甲状腺功能亢进 C.糖尿病
D.呆小症 E.肾上腺皮质功能亢进

答案:B
解析:
基础代谢率(BMR)的高低受多种因素的影响:①使BMR升高的常见因素有甲亢、糖尿病、体温 增高、肾上腺皮质功能亢进、白血病、红细胞增多症等;使BMR降低的常见因素有甲低、肾上腺皮质功能 低下、垂体性肥胖症、肾病综合征等。②甲状腺激素是调节产热活动最重要的体液因素,可显著提高机体 绝大多数组织(如心、肝、骨骼肌等)的耗氧量和产热量。1mg T4可使机体增加产热量约4200kJ,使BMR高28%。甲亢患者产热量明显增加,基础代谢率可升高60%?80%。因此最佳答案是B,而不是C、E。
③呆小症是由于甲状腺激素合成不足或甲状腺功能低下所致,因此其基硪代谢率降低。

We're bringing health care to"where people live and work."So declared Larry Merlo,CEO of CVS Health,an American retail-pharmacy giant,announcing a$69 billion deal to buy Aetna,a heatth insurer.One rationale for the deal-assuming the regulators wave it through-is for the merged firm to develop personalised health care that people can easily get access to.There is another,more defensive,impetus behind the deal-the prospect of Amazon going into prescription medicine.The American pharmaceutical market is an alluring one for the online giant.It is large,worth$450 billion in 2016.And it is widely regarded as inefficient,leaving customers without good information about products they are buying.Compared with books,toys and other bulky items,the drugs market would appear to be a nirvana for Amazon.Prescription medicines weigh almost nothing,take up little space and can cost hundreds or thousands of dollars per pill.But three barriers block the road to this idyll.First,the sale and distribution of drugs is heavily regulated.Amazon would not be able to dump prescription drugs into the same fulfilment channels as its other products.It must acquire pharmaceutical licences for any state where it wishes to operate.Amazon would also need approval from the Food and Drug Administration at a federal level.Operating in a controlled industry would be a departure for a free-wheeling tech firm.Second,most drugs are paid for by insurers,not by consumers.The pharmacy-benefits managers(PBMs),a sort of middlemen that buy drugs for insurers and companies,perform the complex task of matching purchases with patients'insurers,so that drugs are paid for.That is a source of the sort of opacity that Amazon would seek to remove.But the rcommerce firm would still need to handle issues of payment in the background,without keeping asking consumers for insurance details.Third,although drugs do come in small packages,their shipping and handling often require special attention.Many drugs must be kept cold throughout the supply chain.Others are dangerous,and must be kept in locked cages.Yet these drugs are often also the most expensive.If Amazon cherry-picks drugs that fit well into its existing network,it will miss out on a large slice of the market.Customers could find it confusing to be able to get some prescriptions through Amazon's store but not others.Amazon could find itself a partner,however.In July the boss of Express Scripts,a PBM,said it could use Amazon as an"efficient provider in networks".Or Amazon could buy what it needs.It might buy Rite Aid,a big pharmacy chain,giving it licences,a"cold-chain"infrastructure and Rite Aid's small PBM in one swoop.A prospect like that goes a long way to explaining the marriage of CVS and Aetna.
Which of the following would be the best title for the text?

A.The Personalized Health Care:A Dream of Retail-Pharmacy Giants
B.The American Pharmaceutical Market:A Goldmine for Online Giants
C.The Prospect of Amazon's Entry:A Spur to a Massive Deal in Health Care
D.The Marriage of CVS and Aetna:A Tough and Long Road to Go
答案:C
解析:
文章首段指出医疗服务业一起巨额交易“CVS收购Aetna”,随后指出其主要原因“Amazon意欲进军处方药市场”。然后分析指出Amazon直接进军处方药市场存在重重障碍。最后转而指出,但Amazon可以通过迂回方式进入.正是这种可能在很大程度上解释了CVS和Aetna的联姻。可见C.恰合全篇主旨。[排除干扰]A.源自第二段首句“CVS和Aetna合并的部分原因在于想要开发个性化医疗服务”,但该原因一笔带过,并非文章主要关注对象,且这只涉及“CVS-家药品零售巨头”,A Dream of Reta.1一Pharmacy Giants将“个例”夸大为“现象”。B.符合第二段所述事实“美国医药市场蕴藏巨大商机”,但无法涵盖文章其他部分内容,且同A.类似,这里只提及Amazon-家在线巨头.Online Giants将“个例”夸大为“现象”。D.将文章关注案例“CVS和Aetna联姻”以及文中所述“三大障碍(three barriers)”糅杂,文中实际关系为“CVS和Aetna联姻已经宣布;这一联姻很大程度上是为了应对Amazon威胁;而Amazon直接进军处方药市场存在三大障碍”。

声明:本文内容由互联网用户自发贡献自行上传,本网站不拥有所有权,未作人工编辑处理,也不承担相关法律责任。如果您发现有涉嫌版权的内容,欢迎发送邮件至:contact@51tk.com 进行举报,并提供相关证据,工作人员会在5个工作日内联系你,一经查实,本站将立刻删除涉嫌侵权内容。